Corient Private Wealth LP Takes $173.68 Million Position in Abbott Laboratories $ABT

Key Points

• Corient Private Wealth LP acquired 4.94 million Abbott shares worth approximately $173.7 million, giving it a 0.29% stake. Institutional investors collectively own 75.18% of the company.
• Analysts remain broadly positive, with Abbott holding a “Moderate Buy” consensus rating and an average price target of $119.50; several firms recently raised their targets.
• Abbott exceeded quarterly earnings and revenue expectations, with revenue up 13% year over year. The company also pays a quarterly dividend of $0.63 per share, representing a 2.3% yield.

Corient Private Wealth LP bought a new position in shares of Abbott Laboratories (NYSE:ABT - Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 4,940,219 shares of the healthcare product maker's stock, valued at approximately $173,676,000. Corient Private Wealth LP owned about 0.29% of Abbott Laboratories as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. MidAtlantic Capital Management Inc. bought a new stake in shares of Abbott Laboratories in the fourth quarter worth about $25,000. Cornerstone Financial Management LLC bought a new position in Abbott Laboratories during the fourth quarter valued at approximately $25,000. Purpose Unlimited Inc. purchased a new position in Abbott Laboratories during the 4th quarter valued at approximately $25,000. Portfolio Resources Advisor Group Inc. bought a new stake in Abbott Laboratories in the 4th quarter worth approximately $26,000. Finally, Abound Financial LLC bought a new stake in Abbott Laboratories in the 4th quarter worth approximately $26,000. 75.18% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

ABT has been the subject of a number of research reports. Piper Sandler reiterated an "overweight" rating and set a $118.00 target price (up from $115.00) on shares of Abbott Laboratories in a research report on Friday, July 17th. Wolfe Research raised shares of Abbott Laboratories from a "peer perform" rating to an "outperform" rating and set a $130.00 price target on the stock in a research note on Thursday, August 13th. Citigroup increased their price objective on shares of Abbott Laboratories from $108.00 to $112.00 and gave the company a "buy" rating in a research report on Friday, July 17th. Weiss Ratings raised shares of Abbott Laboratories from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Thursday, August 6th. Finally, JPMorgan Chase & Co. upped their target price on shares of Abbott Laboratories from $110.00 to $120.00 and gave the company an "overweight" rating in a research report on Friday, July 17th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $119.50.

Abbott Laboratories Stock Performance

NYSE ABT opened at $110.52 on Thursday. The business's 50 day moving average price is $103.83 and its 200-day moving average price is $100.09. Abbott Laboratories has a fifty-two week low of $81.97 and a fifty-two week high of $137.49. The company has a market cap of $191.24 billion, a P/E ratio of 35.77, a P/E/G ratio of 2.02 and a beta of 0.59. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38.

Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The business had revenue of $12.59 billion during the quarter, compared to the consensus estimate of $12.52 billion. During the same quarter last year, the firm earned $1.26 earnings per share. The firm's quarterly revenue was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Sell-side analysts predict that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th were paid a dividend of $0.63 per share. The ex-dividend date was Wednesday, July 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.3%. Abbott Laboratories's dividend payout ratio (DPR) is currently 81.55%.

Trending Headlines about Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott outperformed the market during the latest trading session, supported by continued investor interest in the diversified healthcare-products maker. Its shares are trading above both the 50-day and 200-day moving averages, indicating favorable near-term momentum. Abbott Exceeds Market Returns: Some Facts to Consider
• Positive Sentiment: Abbott’s latest reported quarter showed solid fundamentals: adjusted earnings exceeded consensus estimates, revenue surpassed expectations, and sales increased 13% year over year. Management’s 2026 earnings guidance remains consistent with analyst expectations, helping support the investment case.
• Neutral Sentiment: Industry research projects continued growth in cardiovascular ultrasound systems through 2030, driven by portable devices, artificial intelligence, 3D/Doppler imaging and remote diagnostics. The opportunity is broadly relevant to Abbott’s cardiovascular-device business, although the report primarily highlights GE HealthCare, Philips and Siemens Healthineers rather than announcing a specific Abbott development. Cardiovascular Ultrasound Systems Market Outlook
• Neutral Sentiment: Recent commentary notes that Abbott has lagged the healthcare sector over the past year, but analysts remain broadly optimistic about its long-term prospects. This creates a mixed backdrop: valuation and relative performance could restrain gains, while analyst confidence and business diversification provide support. Abbott Laboratories Stock: Is ABT Underperforming the Healthcare Sector?

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source